-
 Conference Call Today NNLX
HUBBARD, Ohio, September 22, 2009 /Marketwire -- NanoLogix, Inc. (Pink Sheets: NNLX). NanoLogix’s 2009 Shareholder Meeting will be held Friday, September 25th beginning at 1:00 PM at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, Ohio 44512.
Conference call number: 1-800-567-5900. Access Code is: 278349
HUBBARD, Ohio, September 22, 2009 /Marketwire -- NanoLogix, Inc. (Pink Sheets: NNLX). NanoLogix’s 2009 Shareholder Meeting will be held Friday, September 25th beginning at 1:00 PM at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, Ohio 44512. More information, including a conference access telephone number, can be found at Welcome to Nanologix!. Dr. Sergey Gazenko, the developer of three of the Company’s five detection technologies, will display the BNP™, BNF™, and BNC™ technologies at the meeting.
NanoLogix is nearing completion of its clean room production facility at its Hubbard headquarters and is ordering equipment from New Brunswick Scientific for use in the production of the company’s BNP and BNF ultra-fast detection kits. The BNP and BNF kits are the company’s key components in the development of a water-quality test for the US EPA, with e-coli and other health-threatening microorganism detection times significantly reduced from times achievable with any other culture-based technologies.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases. In addition to medical, National Defense, and Homeland Security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at Welcome to Nanologix!.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
________________________________________
Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: carol@nanologix.com
Copyright 2009 NanoLogix, Inc All Rights Reserved
-
NNLX Conference call Summary
Needless to say, I guess the shareholders and listeners of the conference call today were pretty impressed with what was said of the future of NNLX. A nice honest 20 percent gain today, all during and after the meeting. Very impressive pink sheet company with an actual real tested and proven product moving very close towards production.
-
 Above Average Volume
The volume is already above the 3 month average on this one. Shareholder's meeting was Friday and lots of buys on this one. Needless to say, shareholders were delighted with what they heard and saw.
-
Clean Room Construction Video NNLX
Here's the link that may work better for some users.
http://www.youtube.com/watch?v=TBNv8fgRK...
-
NNLX building a true business
It is funny how many people just look for a quick and fast gainer. A quick buck if you will. Take a look at NNLX. Building a business and they have true third party validation. One would be remiss if they overlooked this gem. (FYI, hold it for more then a day or two. Stash it away in your portfolio)
-
NNLX, A bright future real fast here.
Scroll down to pg 14 and notice NNLX is on this DOD newsletter.
https://www.cbrniac.apgea.army.mil/D...vol10_num3.pdf
Then read this article from USA today. This is what NNLX does.
USA TODAY BIOTERRORISM
By Mimi Hall, USA TODAY
WASHINGTON — The Obama administration is working hard to curb nuclear threats but failing to address the more urgent and immediate threat of biological terrorism, a bipartisan commission created by Congress is reporting today.
The report obtained by USA TODAY cites failures on biosecurity policy by the White House, which the Commission on the Prevention of Weapons of Mass Destruction says has left the country vulnerable. The commission, created last year to address concerns raised by post-9/11 investigations, warns that anthrax spores released by a crop-duster could "kill more Americans than died in World War II" and the economic impact could exceed $1.8 trillion in cleanup and other costs.
The government's efforts "have not kept pace with the increasing capabilities and agility of those who would do harm to the United States," the report says. "The consequences of ignoring these warnings could be dire." Says commission Chairman Bob Graham, a Democratic former senator from Florida: "The clock is ticking."
White House spokesman Nick Shapiro said protecting the nation from deadly weapons is among President Obama's "top national security priorities."
Among the commission's criticisms:
• President Obama's National Security Council has no senior political appointees with a biodefense background. "That was not the case in the Clinton and Bush administrations," the report says.
• Programs created after the 9/11 attacks to develop and buy vaccines and drugs to prevent and respond to a biological attack are not being funded adequately. Although the report is critical of the White House on this topic, Congress has the power of the purse. The report cites a funding shortage for a program to ensure there are enough drugs to respond to a bioterrorist attack.
The Obama administration asked for $305 million in its fiscal 2010 budget request. "Insufficient by a factor of 10," the report says.
• Disease surveillance programs fall short.
The government needs to invest in rapid diagnostic tests to "improve the nation's ability to treat people by providing a more timely and accurate diagnosis" — something that can be critical to treating the victim of a biological attack.
Shapiro says the government is spending $3.5 billion to protect the public from the H1N1 flu and is "carefully evaluating" broader "all-hazards" spending.
Commission Vice Chairman Jim Talent, a Republican former senator from Missouri, says: "The fact is, it is only getting easier and cheaper to develop and use biological weapons. ... It is essential that the U.S. government move more aggressively."
-
PR News for NNLX
Nanologix | Press Releases
NanoLogix Files International Patent Applications, Reclaims 18 Existing Patents, Noted in Department of Defense Quarterly Publication and Provides Operations Update
HUBBARD, Ohio, November 3, 2009 /Marketwire -- NanoLogix, Inc. (Pink Sheets: NNLX) announces that the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU. These applications were filed in order to obtain intellectual property protection for the company’s technology in countries viewed as representing the largest potential international market for BNP rapid detection, a revolutionary sandwiched-membrane Petri-based technology that can reduce microorganism detection times by 100 - 400%.
At the company’s September 25th shareholder meeting, the support for all proposals presented by the company for shareholder approval was overwhelmingly positive, with all shareholder-rights/takeover-defense plan proposals receiving 98-99% of the 64 million shares voted out of roughly 101 million shares outstanding.
The company has reclaimed full rights to 18 patents previously licensed to Nutra Pharma Corporation after failure of Nutra Pharma to pay the balance of patent royalties due for 2008 and the first half of 2009. Nutra Pharma was served notice of their default in July. NanoLogix has returned the 18 patents to the company portfolio and will pursue development and marketing of select technological aspects of the patents.
NanoLogix’s April press release: “New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague”, was highlighted in the latest issue of the Department of Defense Quarterly, CBRNIAC, from the Chemical, Biological, Radiological and Nuclear Defense Information Analysis Center. The publication can be accessed at: https://www.cbrniac.apgea.army.mil/Produ...
NanoLogix has received notification from New Brunswick Scientific of a November 20th shipping date for ordered production equipment for its clean room production facility at the company’s Hubbard, Ohio headquarters. This order consists of four machines for production of BNP rapid-detection kits and is anticipated to be the first of many for kit production.
NanoLogix management, staff, and directors would like to congratulate Corporate Counsel David R. Barnhizer for his recent three-year appointment as Visiting Professor to the University of Westminster, London. Professor Barnhizer will continue as corporate counsel.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases. In addition to medical, National Defense, and Homeland Security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at Welcome to Nanologix!
-
Much Promise NNLX
After yesterday's news, the stock closed at .46, up .07. Their is much to be happy about with NNLX. The ultra fast testing kits were validated by Battelle. The company is now in a DOD news letter. 4 machines are being shipped on the 20th of this month, and the company is set to begin production. They should be able to penetrate the multibillion dollar rapid testing petri dish market, as their dishes have been proven way faster then current technologies. The beauty is it is simple to use and pretty much turn key.
-
NNLX looks promising very soon
With delivery of machinery on November 20th of this month, and volume already off to a good start this morning, NNLX is as promising as a pinksheet stock you will ever find. Do some D.D., lots of it can be found on the Yahoo Message boards.
-
NNLX ready to soar???
NNLX's stock price is holding steady. Check the chart of course. Been hanging around the high .30's and mid .40's for quite a while now. Machinery to produce membranes for Petri dish are due to ship on the 20th of this month. They will be installed in the newly constructed clean room. Production should begin shortly thereafter. Despite some minor delays in estimation of construction completion, everything has been as planned with the company and it appears very close to began production, with customers mentioned such as 3M, Proctor and Gamble, BD, Battelle, DOD?, DHS? EPA slightly different product. Good luck.
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks